EUVIMEDEUVIMED entdecken
Crossref

SRS90 Patey Prize Entrant - JMJD2A epigenetically regulates hepatocellular carcinoma metabolism

Pamela Calle-Mendoza, Beruwalage Fernando, Zahraa Al-Ahmady, Zoi Michailidou, Christos Polytarchou, Maria Hatziapostolou

British Journal of Surgery · 27.03.2026 · 113 (Supplement_2)

DOI: 10.1093/bjs/znag018.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 27.03.2026. Verfasst von Pamela Calle-Mendoza und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is an aggressive malignancy that marks the sixth most common cancer worldwide. Regardless of aetiology, progression of HCC is variable and influenced by non-genetic factors, pointing to its epigenetic nature. Our goal was to characterize epigenetic modifications involved in HCC development and evaluate their potential as therapeutic targets. We have established four liver cancer cell lines resistant to three chemotherapeutic drugs. Transcriptomic profiling revealed up-regulation of lysine demethylase JMJD2A in chemoresistant cells. Screening of 182 epigenetic compounds showed that JMJD2A inhibition suppresses liver cancer cell growth. Oncogenic properties of JMJD2A were verified through a series of functional assays following JMJD2A knockdown. Specifically, by employing colorimetric and luminescence-based assays, JMJD2A knockdown significantly suppressed liver cancer cell growth. Similarly, stem cell properties were also affected by JMJD2A knockdown, as assessed by spheroid formation assays and expression analyses of cancer stem cell markers. Importantly, RNA-Sequencing profiling and bioinformatic analyses revealed that metabolic pathways are predicted to be significantly dysregulated. We have further employed microRNA profiling and identified microRNA-137 (miR-137) as a possible regulator of JMJD2A expression. The regulatory role of miR-137 was verified by RT-qPCR and western blot. Finally, through immunohistochemical and RT-qPCR analyses, we show that JMJD2A expression is increased in liver cancer tissues and positively correlated with disease progression. Our final goal is to explore the therapeutic potential of JMJD2A, using inhibitors and/or microRNA mimics, by employing a novel liver cancer-on-a-chip technology.

Zitieren

APA

Calle-Mendoza, P., Fernando, B., Al-Ahmady, Z., Michailidou, Z., Polytarchou, C., & Hatziapostolou, M. (2026). SRS90 Patey Prize Entrant - JMJD2A epigenetically regulates hepatocellular carcinoma metabolism. British Journal of Surgery, 113(Supplement_2). https://doi.org/10.1093/bjs/znag018.010

Vancouver

Calle-Mendoza P, Fernando B, Al-Ahmady Z, Michailidou Z, Polytarchou C, Hatziapostolou M. SRS90 Patey Prize Entrant - JMJD2A epigenetically regulates hepatocellular carcinoma metabolism. British Journal of Surgery. 2026;113(Supplement_2). doi:10.1093/bjs/znag018.010

BibTeX
@article{CalleMendoza2026,
  author = {Calle-Mendoza, Pamela and Fernando, Beruwalage and Al-Ahmady, Zahraa and Michailidou, Zoi and Polytarchou, Christos and Hatziapostolou, Maria},
  title = {SRS90 Patey Prize Entrant - JMJD2A epigenetically regulates hepatocellular carcinoma metabolism},
  journal = {British Journal of Surgery},
  year = {2026},
  volume = {113},
  number = {Supplement_2},
  doi = {10.1093/bjs/znag018.010}
}
Kostenlos starten →